The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients. Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.
Study Type
OBSERVATIONAL
Enrollment
60
Analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the peripheral blood
Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf
Düsseldorf, Germany
RECRUITINGCTC detection
Detection of circulating tumor cells (CTCs) in the peripheral blood
Time frame: Time of enrollment (BL)
ctDNA detection
Detection of circulating tumor DNA (ctDNA) in serum
Time frame: Time of enrollment (BL)
CTC mutation profile
Mutations in oncogenes and tumor suppressor genes
Time frame: Time of CTC analysis (BL)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.